These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8713980)

  • 1. Identification of agonist binding sites of vasopressin and oxytocin receptors.
    Mouillac B; Chini B; Balestre MN; Jard S; Barberis C; Manning M; Tribollet E; Trumpp-Kallmeyer S; Hoflack J; Elands J
    Adv Exp Med Biol; 1995; 395():301-10. PubMed ID: 8713980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions.
    Mouillac B; Chini B; Balestre MN; Elands J; Trumpp-Kallmeyer S; Hoflack J; Hibert M; Jard S; Barberis C
    J Biol Chem; 1995 Oct; 270(43):25771-7. PubMed ID: 7592759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family.
    Chini B; Mouillac B; Ala Y; Balestre MN; Cotte N; Trumpp-Kallmeyer S; Hoflack J; Elands J; Hibert M; Manning M
    Adv Exp Med Biol; 1995; 395():321-8. PubMed ID: 8713982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.
    Chini B; Mouillac B; Ala Y; Balestre MN; Trumpp-Kallmeyer S; Hoflack J; Elands J; Hibert M; Manning M; Jard S
    EMBO J; 1995 May; 14(10):2176-82. PubMed ID: 7774575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
    Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.
    Cotte N; Balestre MN; Aumelas A; Mahé E; Phalipou S; Morin D; Hibert M; Manning M; Durroux T; Barberis C; Mouillac B
    Eur J Biochem; 2000 Jul; 267(13):4253-63. PubMed ID: 10866830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling.
    Postina R; Kojro E; Fahrenholz F
    Adv Exp Med Biol; 1998; 449():371-85. PubMed ID: 10026828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the binding sites of the SR49059 nonpeptide antagonist into the V1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors.
    Tahtaoui C; Balestre MN; Klotz P; Rognan D; Barberis C; Mouillac B; Hibert M
    J Biol Chem; 2003 Oct; 278(41):40010-9. PubMed ID: 12869559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin.
    Chini B; Mouillac B; Balestre MN; Trumpp-Kallmeyer S; Hoflack J; Hibert M; Andriolo M; Pupier S; Jard S; Barberis C
    FEBS Lett; 1996 Nov; 397(2-3):201-6. PubMed ID: 8955347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular recognition of peptide and non-peptide ligands by the extracellular domains of neurohypophysial hormone receptors.
    Howl J; Wheatley M
    Biochem J; 1996 Jul; 317 ( Pt 2)(Pt 2):577-82. PubMed ID: 8713088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docking ligands to vasopressin and oxytocin receptors via genetic algorithm.
    Politowska E; Drabik P; Kazmierkiewicz R; Ciarkowsk J
    J Recept Signal Transduct Res; 2002; 22(1-4):393-409. PubMed ID: 12503629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin.
    Gimpl G; Postina R; Fahrenholz F; Reinheimer T
    Eur J Pharmacol; 2005 Mar; 510(1-2):9-16. PubMed ID: 15740719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ; Slusarz R; Ciarkowski J
    Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of F-180: a selective human V(1a) vasopressin receptor agonist of high affinity.
    Andrés M; Trueba M; Guillon G
    Br J Pharmacol; 2002 Apr; 135(7):1828-36. PubMed ID: 11934825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptor.
    Breton C; Chellil H; Kabbaj-Benmansour M; Carnazzi E; Seyer R; Phalipou S; Morin D; Durroux T; Zingg H; Barberis C; Mouillac B
    J Biol Chem; 2001 Jul; 276(29):26931-41. PubMed ID: 11337500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of ligand binding and receptor activation in the oxytocin and vasopressin receptor family.
    Chini B; Fanelli F
    Exp Physiol; 2000 Mar; 85 Spec No():59S-66S. PubMed ID: 10795907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional architecture of vasopressin/oxytocin receptors.
    Hibert M; Hoflack J; Trumpp-Kallmeyer S; Mouillac B; Chini B; Mahé E; Cotte N; Jard S; Manning M; Barberis C
    J Recept Signal Transduct Res; 1999; 19(1-4):589-96. PubMed ID: 10071787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separate agonist and peptide antagonist binding sites of the oxytocin receptor defined by their transfer into the V2 vasopressin receptor.
    Postina R; Kojro E; Fahrenholz F
    J Biol Chem; 1996 Dec; 271(49):31593-601. PubMed ID: 8940177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin-modeling of an activated state.
    Slusarz MJ; Slusarz R; Ciarkowski J
    J Pept Sci; 2006 Mar; 12(3):171-9. PubMed ID: 16114099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus.
    Hawtin SR; Wesley VJ; Parslow RA; Patel S; Wheatley M
    Biochemistry; 2000 Nov; 39(44):13524-33. PubMed ID: 11063589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.